← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Bisphosphonates, combinations
risedronic acid and calcium, sequential
M05BB02
Forms & Strengths
- Sequential kit: risedronate sodium 35 mg tablets and calcium carbonate 500 mg tablets
Adult Dosing
- Postmenopausal osteoporosis: One risedronate 35 mg tablet once weekly on day 1, followed by one calcium carbonate 500 mg tablet daily on the remaining 6 days (days 2 through 7)
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment and prevention of osteoporosis in postmenopausal women
Mechanism of Action
- Risedronate is a bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption, reducing bone turnover; calcium is a dietary supplement required for maintenance of skeletal integrity
Contraindications
- Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia
- Inability to stand or sit upright for at least 30 minutes
- Hypocalcemia
- Known hypersensitivity to risedronate, calcium, or any component
Adverse Reactions
- Abdominal pain
- Dyspepsia
- Nausea
- Constipation
- Diarrhea
- Musculoskeletal pain
- Headache
- Rare: osteonecrosis of the jaw, atypical femoral fractures, esophageal ulceration
Drug Interactions
- Antacids and polyvalent cation-containing products interfere with the absorption of risedronate and calcium
- Calcium supplements may decrease the absorption of various medications if taken concurrently
- Aspirin or NSAIDs may increase gastrointestinal adverse effects
Curated Content: Needs Vetting Before Put to Clinical Use